DK3036329T3 - Immunonkolytiske terapier - Google Patents
Immunonkolytiske terapier Download PDFInfo
- Publication number
- DK3036329T3 DK3036329T3 DK14837931.6T DK14837931T DK3036329T3 DK 3036329 T3 DK3036329 T3 DK 3036329T3 DK 14837931 T DK14837931 T DK 14837931T DK 3036329 T3 DK3036329 T3 DK 3036329T3
- Authority
- DK
- Denmark
- Prior art keywords
- immunoncolytical
- therapies
- immunoncolytical therapies
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
- A61K35/768—Oncolytic viruses not provided for in groups A61K35/761 - A61K35/766
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
- A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24121—Viruses as such, e.g. new isolates, mutants or their genomic sequences
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24132—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24171—Demonstrated in vivo effect
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Virology (AREA)
- Organic Chemistry (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Immunology (AREA)
- Mycology (AREA)
- Oncology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Hematology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361868978P | 2013-08-22 | 2013-08-22 | |
| PCT/US2014/052308 WO2015027163A1 (en) | 2013-08-22 | 2014-08-22 | Immuno-oncolytic therapies |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK3036329T3 true DK3036329T3 (da) | 2021-01-11 |
Family
ID=52484194
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK14837931.6T DK3036329T3 (da) | 2013-08-22 | 2014-08-22 | Immunonkolytiske terapier |
| DK20189155.3T DK3778897T3 (da) | 2013-08-22 | 2014-08-22 | Immunonkolytiske terapier |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK20189155.3T DK3778897T3 (da) | 2013-08-22 | 2014-08-22 | Immunonkolytiske terapier |
Country Status (28)
| Country | Link |
|---|---|
| US (2) | US11478518B2 (da) |
| EP (3) | EP4324918A3 (da) |
| JP (3) | JP6912199B2 (da) |
| KR (1) | KR102389240B1 (da) |
| CN (1) | CN105658795B (da) |
| AU (1) | AU2014308648B2 (da) |
| CA (3) | CA2921041C (da) |
| DK (2) | DK3036329T3 (da) |
| EA (1) | EA037582B1 (da) |
| ES (2) | ES2847305T3 (da) |
| FI (1) | FI3778897T3 (da) |
| HK (1) | HK1223402A1 (da) |
| HR (1) | HRP20240078T1 (da) |
| HU (1) | HUE066593T2 (da) |
| IL (1) | IL243996A0 (da) |
| LT (1) | LT3778897T (da) |
| MD (2) | MD4748C1 (da) |
| MX (1) | MX2016002257A (da) |
| NZ (1) | NZ716825A (da) |
| PE (1) | PE20160673A1 (da) |
| PH (1) | PH12016500329A1 (da) |
| PL (1) | PL3778897T3 (da) |
| PT (1) | PT3778897T (da) |
| RS (1) | RS65104B1 (da) |
| SG (1) | SG11201600960PA (da) |
| SI (1) | SI3778897T1 (da) |
| SM (1) | SMT202400047T1 (da) |
| WO (1) | WO2015027163A1 (da) |
Families Citing this family (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4324918A3 (en) | 2013-08-22 | 2024-04-24 | University of Pittsburgh - of The Commonwealth System of Higher Education | Immuno-oncolytic therapies |
| EP3261669B1 (en) | 2015-02-25 | 2022-08-03 | Memorial Sloan Kettering Cancer Center | Use of inactivated nonreplicating modified vaccinia virus ankara (mva)as monoimmunotherapy or in combination with immune checkpoint blocking agents for solid tumors |
| EP3283088A4 (en) | 2015-04-17 | 2018-10-24 | Memorial Sloan-Kettering Cancer Center | Use of mva or mvadeltae3l as immunotherapeutic agents against solid tumors |
| EP3327137B1 (en) * | 2015-07-22 | 2020-12-09 | National University Corporation Tottori University | Host regulation factor for enhancing proliferation and propagation of vaccinia virus |
| JP6895968B2 (ja) * | 2015-09-08 | 2021-06-30 | シルラジェン インコーポレイテッド | サイトカインおよびカルボキシルエステラーゼを発現する腫瘍溶解性改変ワクシニアウイルス、および、その使用方法 |
| US20190038713A1 (en) | 2015-11-07 | 2019-02-07 | Multivir Inc. | Compositions comprising tumor suppressor gene therapy and immune checkpoint blockade for the treatment of cancer |
| CN116440176A (zh) | 2016-02-25 | 2023-07-18 | 纪念斯隆凯特琳癌症中心 | 具有胸苷激酶缺失和具有或不具有人flt3l或gm-csf表达的复制型减毒痘苗病毒 |
| JP7034080B2 (ja) | 2016-02-25 | 2022-03-11 | メモリアル スローン ケタリング キャンサー センター | ヒトｆｌｔ３ｌを発現する組換えｍｖａまたはｍｖａδｅ３ｌおよび固形腫瘍に対する免疫療法薬としてのそれらの使用 |
| KR20190007416A (ko) * | 2016-03-25 | 2019-01-22 | 유니버시티 오브 피츠버그 - 오브 더 커먼웰쓰 시스템 오브 하이어 에듀케이션 | 합성적으로 엔벨롭된 바이러스 |
| EP3254692A1 (en) | 2016-06-10 | 2017-12-13 | Ceva Sante Animale | Multivalent recombinant spv |
| AU2017298385A1 (en) | 2016-07-19 | 2019-03-07 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Oncolytic viruses targeting STAT3 |
| AU2017332367B2 (en) * | 2016-09-21 | 2021-12-23 | Stephen H. Thorne | High mobility group box i mutant |
| GB201616365D0 (en) | 2016-09-27 | 2016-11-09 | Helsingin Yliopisto | Non-genetic modification of enveloped viruses |
| CN110381997A (zh) | 2016-12-12 | 2019-10-25 | 茂体外尔公司 | 用于治疗和预防癌症和感染性疾病的包含病毒基因治疗和免疫检查点抑制剂的方法和组合物 |
| CA3052463A1 (en) * | 2017-02-03 | 2018-08-09 | University Of Pittsburgh-Of The Commonwealth System Of Higher Education | Oncolytic virus therapy |
| US20180252729A1 (en) * | 2017-03-06 | 2018-09-06 | University Of Louisville Research Foundation | Methods and compositions for determining the potency of a therapeutic cellular composition |
| KR20190137911A (ko) * | 2017-04-21 | 2019-12-11 | 신라젠(주) | 항암 백시니아 바이러스와 관문 저해제 병용 요법 |
| CN111107872A (zh) | 2017-05-12 | 2020-05-05 | 纪念斯隆-凯特林癌症中心 | 有用于癌症免疫疗法的牛痘病毒突变体 |
| WO2019089755A1 (en) * | 2017-10-31 | 2019-05-09 | Western Oncolytics Ltd. | Platform oncolytic vector for systemic delivery |
| EP3717000A1 (en) | 2017-12-01 | 2020-10-07 | Gerd Sutter | Immuno-modulated replication-efficient vaccinia virus strain |
| US11802292B2 (en) * | 2018-01-05 | 2023-10-31 | Ottawa Hospital Research Institute | Modified orthopoxvirus vectors |
| KR20200135986A (ko) | 2018-03-19 | 2020-12-04 | 멀티비르 인코포레이티드 | 종양 억제인자 유전자 치료 및 cd122/cd132 작용제를 포함하는 암 치료를 위한 방법 및 조성물 |
| KR20210032495A (ko) * | 2018-07-20 | 2021-03-24 | 안선 바이오파르마, 아이엔씨. | 암 세포, 면역 세포 및 종양 미세환경에 시알리다제의 전달 |
| BR112021004692A2 (pt) | 2018-09-15 | 2021-06-08 | Memorial Sloan Kettering Cancer Center | poxvírus recombinantes para imunoterapia de câncer |
| CA3124287A1 (en) * | 2018-12-21 | 2020-06-25 | Ottawa Hospital Research Institute | Modified orthopoxvirus vectors |
| AU2020207040A1 (en) * | 2019-01-07 | 2021-07-15 | Kalivir Immunotherapeutics, Inc. | Methods of treating cancer |
| TW202038994A (zh) * | 2019-01-14 | 2020-11-01 | 美商醫格耐免疫治療公司 | 重組痘瘡病毒及其使用方法 |
| EP3923967A1 (en) | 2019-02-14 | 2021-12-22 | Ignite Immunotherapy, Inc. | Recombinant vaccinia virus and methods of use thereof |
| CA3151975A1 (en) * | 2019-10-16 | 2021-04-22 | Stephen H. Thorne | Modified extracellular enveloped virus |
| EP4061417A4 (en) * | 2019-11-20 | 2023-10-11 | University of Pittsburgh - of the Commonwealth System of Higher Education | VACCINE VIRUSES AND METHODS OF USING VACCINE VIRUSES |
| WO2021113644A1 (en) | 2019-12-05 | 2021-06-10 | Multivir Inc. | Combinations comprising a cd8+ t cell enhancer, an immune checkpoint inhibitor and radiotherapy for targeted and abscopal effects for the treatment of cancer |
| JP2021106576A (ja) * | 2019-12-12 | 2021-07-29 | イグナイト・イミュノセラピー，インコーポレーテッド | 変異体腫瘍溶解性ワクシニアウイルスおよびその使用法 |
| CA3167002A1 (en) * | 2020-01-09 | 2021-07-15 | Pfizer Inc. | Recombinant vaccinia virus |
| EP4114448A4 (en) * | 2020-03-06 | 2024-04-03 | University of Pittsburgh - Of the Commonwealth System of Higher Education | Irf modulator-expressing oncolytic viruses for treating cancer |
| CA3215344A1 (en) * | 2021-04-30 | 2022-11-03 | Kalivir Immunotherapeutics, Inc. | Oncolytic viruses for modified mhc expression |
| AU2022303363A1 (en) * | 2021-06-29 | 2024-01-18 | Flagship Pioneering Innovations V, Inc. | Immune cells engineered to promote thanotransmission and uses thereof |
| WO2023106839A1 (ko) * | 2021-12-07 | 2023-06-15 | 재단법인 아산사회복지재단 | Il-12를 발현하는 재조합 백시니아 바이러스 및 이의 용도 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004014314A2 (en) * | 2002-08-12 | 2004-02-19 | David Kirn | Methods and compositions concerning poxviruses and cancer |
| JPWO2007023725A1 (ja) * | 2005-08-25 | 2009-02-26 | 公立大学法人横浜市立大学 | 遺伝子ワクチン |
| US8980246B2 (en) * | 2005-09-07 | 2015-03-17 | Sillajen Biotherapeutics, Inc. | Oncolytic vaccinia virus cancer therapy |
| US9180149B2 (en) * | 2005-09-07 | 2015-11-10 | Sillajen Biotherapeutics, Inc. | Systemic treatment of metastatic and/or systemically-disseminated cancers using GM-CSF-expressing poxviruses |
| AU2012244210B2 (en) * | 2005-09-07 | 2014-10-02 | Sillajen Biotherapeutics, Inc. | Systemic treatment of metastatic and/or systemically-disseminated cancers using gm-csf-expressing poxviruses |
| KR20080084528A (ko) * | 2007-03-15 | 2008-09-19 | 제네렉스 바이오테라퓨틱스 인크. | 종양살상형 백시니아 바이러스 암 치료 |
| WO2009124044A2 (en) * | 2008-03-31 | 2009-10-08 | University Of Florida Research Foundation, Inc. | Tumor growth inhibition via conditioning of tumor microenvironment |
| KR101759888B1 (ko) | 2009-09-14 | 2017-07-20 | 신라젠(주) | 종양 용해 백시니아 바이러스 병용 암 치료요법 |
| US20130202639A1 (en) | 2010-03-25 | 2013-08-08 | Konstantin G. Kousoulas | Synthetic Herpes Simplex Viruses for Treatment of Cancers |
| CN104093830A (zh) * | 2011-04-15 | 2014-10-08 | 吉恩勒克斯公司 | 减毒的痘苗病毒的克隆毒株及其使用方法 |
| WO2014047350A1 (en) * | 2012-09-20 | 2014-03-27 | Morningside Technology Ventures Ltd. | Oncolytic virus encoding pd-1 binding agents and uses of the same |
| EP4324918A3 (en) | 2013-08-22 | 2024-04-24 | University of Pittsburgh - of The Commonwealth System of Higher Education | Immuno-oncolytic therapies |
-
2014
- 2014-08-22 EP EP23215391.6A patent/EP4324918A3/en active Pending
- 2014-08-22 MD MDA20180086A patent/MD4748C1/ro active IP Right Grant
- 2014-08-22 SM SM20240047T patent/SMT202400047T1/it unknown
- 2014-08-22 DK DK14837931.6T patent/DK3036329T3/da active
- 2014-08-22 AU AU2014308648A patent/AU2014308648B2/en active Active
- 2014-08-22 KR KR1020167006785A patent/KR102389240B1/ko active Active
- 2014-08-22 FI FIEP20189155.3T patent/FI3778897T3/fi active
- 2014-08-22 ES ES14837931T patent/ES2847305T3/es active Active
- 2014-08-22 CA CA2921041A patent/CA2921041C/en active Active
- 2014-08-22 PT PT201891553T patent/PT3778897T/pt unknown
- 2014-08-22 SI SI201432060T patent/SI3778897T1/sl unknown
- 2014-08-22 EP EP20189155.3A patent/EP3778897B1/en active Active
- 2014-08-22 SG SG11201600960PA patent/SG11201600960PA/en unknown
- 2014-08-22 EA EA201690444A patent/EA037582B1/ru unknown
- 2014-08-22 WO PCT/US2014/052308 patent/WO2015027163A1/en active Application Filing
- 2014-08-22 MX MX2016002257A patent/MX2016002257A/es unknown
- 2014-08-22 CA CA3213683A patent/CA3213683A1/en active Pending
- 2014-08-22 CA CA3213715A patent/CA3213715A1/en active Pending
- 2014-08-22 MD MD20160027A patent/MD4624C1/ro active IP Right Grant
- 2014-08-22 CN CN201480058401.0A patent/CN105658795B/zh active Active
- 2014-08-22 JP JP2016536482A patent/JP6912199B2/ja active Active
- 2014-08-22 EP EP14837931.6A patent/EP3036329B1/en active Active
- 2014-08-22 RS RS20240082A patent/RS65104B1/sr unknown
- 2014-08-22 LT LTEP20189155.3T patent/LT3778897T/lt unknown
- 2014-08-22 NZ NZ716825A patent/NZ716825A/en unknown
- 2014-08-22 DK DK20189155.3T patent/DK3778897T3/da active
- 2014-08-22 PE PE2016000287A patent/PE20160673A1/es unknown
- 2014-08-22 ES ES20189155T patent/ES2971528T3/es active Active
- 2014-08-22 PL PL20189155.3T patent/PL3778897T3/pl unknown
- 2014-08-22 HR HRP20240078TT patent/HRP20240078T1/hr unknown
- 2014-08-22 HU HUE20189155A patent/HUE066593T2/hu unknown
-
2016
- 2016-02-07 IL IL243996A patent/IL243996A0/en unknown
- 2016-02-18 PH PH12016500329A patent/PH12016500329A1/en unknown
- 2016-02-19 US US15/048,698 patent/US11478518B2/en active Active
- 2016-10-12 HK HK16111742.0A patent/HK1223402A1/zh unknown
-
2019
- 2019-07-19 JP JP2019133264A patent/JP7021154B2/ja active Active
-
2022
- 2022-02-03 JP JP2022015459A patent/JP7333431B2/ja active Active
- 2022-09-07 US US17/939,707 patent/US20230008089A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK3778897T3 (da) | Immunonkolytiske terapier | |
| DK3342773T3 (da) | Syk-hæmmere | |
| DK3613453T3 (da) | Fordamper | |
| DK3077047T3 (da) | Aramcholsalte | |
| PT3055308T (pt) | Resumo | |
| DK2956698T3 (da) | Bindestrimler | |
| DK3060460T3 (da) | Saddel | |
| DK3027598T3 (da) | Oxoquinazolinyl-butanamidderivater | |
| EP2952513A4 (en) | AZOLE AND BENZENE DERIVATIVE | |
| DK3052081T3 (da) | Pastil | |
| DK2946640T3 (da) | Langmuir-probe | |
| EP2969096A4 (en) | Bottle pressurization delivery system | |
| EP2991647A4 (en) | DEUTERED AMLEXANOX | |
| EP2943489A4 (en) | DEUTERATED MOMELOTINIB | |
| EP2970310A4 (en) | 5-BROMO-indirubins | |
| DE102013106534B8 (de) | Chromatographiepipettenspitze | |
| DK3071227T3 (da) | Fiskevaccine | |
| DE112014001252A5 (de) | Aufbissschiene | |
| DK2981168T3 (da) | Laminitiskile | |
| DK3086679T3 (da) | Sportssko | |
| FI10138U1 (fi) | Kelkkateltta | |
| ES1078715Y (es) | Mosquitera | |
| DE112014005422A5 (de) | Friktionsfalschdrallaggregat | |
| BR112016000501A2 (pt) | Nalador | |
| ES1100380Y (es) | Trompo |